Evidence map›Paper›PMID 42434440›Full record

ReviewInternational journal of pharmaceutics: X2026

Liver fibrosis: Pathogenesis and innovative nanoparticle-based therapeutic strategies.

Yibin Cai, Jiayin Li, Shenyu Chen, Hui Zhang, Jie Tan, Hao Li, Shuyuan Zhang, Boran Li, Qin Wei, Chenshi Lin and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yibin CaiDepartment of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Jiayin LiNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China.
Shenyu ChenFaculty of Medicine, The University of Queensland, Brisbane, Australia.
Hui ZhangSchool of Pharmacy, Fujian Medical university, Fuzhou 350122, China.
Jie TanSchool of Pharmacy, Fujian Medical university, Fuzhou 350122, China.
Hao LiSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Shuyuan ZhangSchool of Business, China Pharmaceutical University, Nanjing 210009, China.
Boran LiSchool of Business, China Pharmaceutical University, Nanjing 210009, China.
Qin WeiSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Chenshi LinSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Xuesong ZhongSchool of Pharmacy, Fujian Medical university, Fuzhou 350122, China.
Xiuhua YouSchool of Pharmacy, Fujian Medical university, Fuzhou 350122, China.
Chao QinSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Chao TengSchool of Pharmacy, Fujian Medical university, Fuzhou 350122, China.
Jie LiuDepartment of Pharmacy, Jiujiang Traditional Chinese Medicine Hospital Affiliated to Jiangxi University of Traditional Chinese Medicine, Jiujiang 332000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver fibrosis is a dynamic pathological process characterized by excessive extracellular matrix (ECM) deposition, primarily driven by the activation of hepatic stellate cells (HSCs). Recent advances in liver fibrosis research have identified critical pathways, such as oxidative stress, inflammation and transforming growth factor-β (TGF-β) signaling, which drive disease progression. Concurrently, innovative drug delivery systems (e.g., liposomes, micelles and nanocrystals) have emerged to enhance therapeutic efficacy and targeting. These systems enable precise delivery of antifibrotic agents to HSCs or fibrotic tissues, minimizing off-target effects and improving pharmacokinetic profiles. This review summarizes current understanding of liver fibrosis pathogenesis and recent advances in drug delivery strategies, highlighting clinical transformation opportunities and future research directions. Combining molecular insights with advanced delivery technologies represents a promising avenue for developing effective antifibrotic therapies.

Indexed as

Extracellular matrixHepatic stellate cellsLiver fibrosisTargeted delivery

Identifiers

PMID42434440
PMCPMC13351183

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.